Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)

Andrés F. Cardona*, Alejandro Ruiz-Patiño, Gonzalo Recondo, Claudio Martín, Luis Raez, Suraj Samtani, José Nicolas Minata, Juan Bautista Blaquier, Diego Enrico, Mauricio Burotto, Camila Ordóñez-Reyes, Diego F. Chamorro, Juan Esteban Garcia-Robledo, Luis Corrales, Zyanya Lucia Zatarain-Barrón, Luis Más, Carolina Sotelo, Luisa Ricaurte, Nicolas Santoyo, Mauricio CuelloSergio Mejía, Elvira Jaller, Carlos Vargas, Hernán Carranza, Jorge Otero, July Rodríguez, Pilar Archila, Maritza Bermudez, Tatiana Gamez, Vladmir Cordeiro de Lima, Helano Freitas, Alessandro Russo, Carolina Polo, Umberto Malapelle, Diego de Miguel Perez, Christian Rolfo, Lucia Viola, Rafael Rosell, Oscar Arrieta

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)'. Together they form a unique fingerprint.

Medicine & Life Sciences